Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
- PMID: 25684504
- DOI: 10.7314/apjcp.2015.16.2.661
Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
Retraction in
-
Retraction Notice to: Normalization of CA19-9 Following Resection for Pancreatic Ductal Adenocarcinoma is not Tantamount to being Cured?Asian Pac J Cancer Prev. 2015;16(13):5587. doi: 10.7314/APJCP.2015.16.13.5587. Asian Pac J Cancer Prev. 2015. PMID: 26225716 No abstract available.
Abstract
Background: Postoperative carbohydrate antigen 19-9 (CA19-9) is an independent predictor of survival for pancreatic ductal adenocarcinoma (PDAC), and more powerful than preoperative CA19-9. However, making decisions just dependent on postoperative CA19-9 may result in necessary treatments not being performed.
Materials and methods: A total of 178 patients with resected PDAC were eligible for this retrospective study, classified into two corresponding subgroups according to postoperative CA19-9. Prognostic significance of all clinicopathologic factors was evaluated by univariate and multivariate analyses.
Results: Postoperative CA19-9, preoperative CA125 and lymph node status were independent predictors. Better predictive performances for overall survival (OS) and recurrence-free survival (RFS) were achieved by postoperative CA19-9 compared to preoperative CA125 and lymph node status. Particularly, preoperative CA125 was associated with poor OS (p<0.001 for the normalized CA19-9 patients, p=0.012 for the elevated) and RFS (p=0.005 for the normalized, p=0.004 for the elevated). Moreover, preoperative CA125 levels related with survival in double- negative patients.
Conclusions: Normalization of CA19-9 is not tantamount to be cured. Preoperative CA125 is a critical predictor for PDAC patients, especially in double-negative patients.
Similar articles
-
CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.Ann Surg Oncol. 2018 Nov;25(12):3483-3491. doi: 10.1245/s10434-018-6521-7. Epub 2018 May 21. Ann Surg Oncol. 2018. PMID: 29786131
-
Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma.Medicine (Baltimore). 2015 May;94(19):e751. doi: 10.1097/MD.0000000000000751. Medicine (Baltimore). 2015. PMID: 25984661 Free PMC article.
-
Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.Surgery. 2017 Feb;161(2):373-384. doi: 10.1016/j.surg.2016.08.005. Epub 2016 Nov 9. Surgery. 2017. PMID: 27838102
-
Comparison of clinical usefulness of serum Ca125 and CA19-9 in pancreatic adenocarcinoma diagnosis: meta-analysis and systematic review of literature.Biomarkers. 2021 Jun;26(4):287-295. doi: 10.1080/1354750X.2021.1876770. Epub 2021 Jan 31. Biomarkers. 2021. PMID: 33459070
-
The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer.Can J Gastroenterol Hepatol. 2018 Aug 14;2018:5389820. doi: 10.1155/2018/5389820. eCollection 2018. Can J Gastroenterol Hepatol. 2018. PMID: 30186820 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous